Caveolae and Lipid Rafts: Structure and Signalling Functions
Lipid rafts (ordered liquid phase (Lo) microdomains in plasma membrane; enriched in cholesterol + sphingomyelin (SM; high Tm → stable gel-like packing); cholesterol fills acyl chain interstices → Lo domain; distinct from disordered Ld (liquid-disordered) phase; raft proteins: GPI-anchored proteins (CD59/CD55/urokinase receptor/Thy-1); src-family kinases (Lyn/Lck/Fyn Cys palmitoylation → raft targeting); Gαs/Gαi/Gαq subunits; receptor tyrosine kinases (EGFR/VEGFR2/IR/IGFR1 raft partitioning modulates signalling fidelity); flotillins/reggies (lipid raft scaffolds; FLOT1/FLOT2; raft-associated); methods: DRM (detergent-resistant membrane; Triton X-100 insoluble at 4°C; raft isolation)); caveolae (flask-shaped invaginations 60–80 nm; caveolin-1/2/3 (CAV1/2/3; hairpin-loop TM; palmitoylation; CAV1 dimerises at Tyr14 via Src; CSD (caveolin scaffolding domain; aa 82–101; interacts with eNOS/Gα/EGFR/PKC/H-Ras); CAV1 tumour suppressor (CAV1 loss in many cancers; raft disruption); CAV2 (co-localises with CAV1; necessary for CAV1 raft insertion); CAV3 (muscle; sarcolemmal; β2-AR and eNOS); Cavin-1/2/3/4 (accessory; PTRF/SDPR; coat caveolae; required for caveolae biogenesis); caveolae functions: (1) endocytosis (caveolae-mediated internalisation; albumin/cholesterol/SV40/LPS); (2) signalling platforms (eNOS (Gly2-palmitoylated → caveolae; CSD-eNOS interaction: CSD Phe92 → eNOS reductase domain → eNOS inhibited (basal “parking”); VEGF/Ca2+-calmodulin → eNOS displacement from CAV1–CSD → eNOS activation); EGFR (raft → EGFR clustering → TKA; CAV1-CSD → EGFR TKA → quiescence outside raft)); (3) mechanosensing (caveolae buffer membrane tension; shear stress → caveolae flattening → lipid release → membrane area increase); (4) cholesterol homeostasis (caveolae cholesterol reservoir; ABCA1-caveolae interaction for RCT).
Spirulina Mechanisms in Caveolae/Lipid Raft Signalling
Cholesterol/Sphingomyelin Raft Composition Modulation
Raft integrity depends critically on cholesterol (optimal membrane cholesterol 30–40 mol%; below: Lo domain dissolves; above: gel-phase crystallisation; raft cholesterol → sphingomyelin (SM; palmitoylated ceramide-phosphocholine; SM:cholesterol ratio in Lo ~1:1); ceramide (from aSMase: SM → ceramide; ceramide → gel-phase clusters (“ceramide-enriched platforms” or CELP); ceramide-rafts favour death receptor (TNFR1/DR4/DR5) clustering → apoptosis/inflammation; ceramide also displaces cholesterol from Lo → raft disruption)): spirulina modulates raft lipid composition: (1) AMPK → HMGCR pSer872 → cholesterol synthesis ↓ −15–25% (mevalonate ↓) → cellular cholesterol ↓ moderately; LDL-C −5–12%; reduced cholesterol loading of rafts → raft size/stability fine-tuning (raft disruption NOT goal; optimal Lo:Ld balance); (2) ceramide ↓ (NF-κB ↓ → aSMase ↓ → ceramide ↓ −20–30% per S1P/ceramide rheostat data) → ceramide-platform reduction → TNFR1/DR5 clustering ↓ (inflammatory CELP ↓); (3) S1P ↑ (SPHK1 → S1P; S1P → SM synthesis by reverse ceramidase → SM ↑ → Lo domain stabilisation; S1PR1 → ABCA1 → cholesterol efflux from non-raft to raft normalisation); SM:ceramide ratio improvement → stabilised physiological rafts, disrupted pathological ceramide-death platforms.
Caveolin-1 Expression and eNOS Caveolae Cycling
CAV1 (caveolin-1; the structural scaffold of caveolae; CSD Phe92 is critical for protein interactions; CAV1 Tyr14 phosphorylation by Src (activated by H2O2/growth factors) → CAV1-Src activation → Src downstream cascade; also CAV1 pTyr14 → FAK activation → focal adhesion; CAV1 eNOS regulation: CAV1-CSD–eNOS interaction → basal eNOS inhibition (tonic NO suppression in non-stimulated endothelium); VEGF/bradykinin/Ca2+ → calmodulin → displaces CAV1-CSD from eNOS → eNOS activation → NO burst; without CAV1: constitutively active eNOS but “uncapped” → chronic NO ↑ → S-nitrosation/unregulated effects; CAV1 also limits EGFR TKA (CAV1-CSD → EGFR kinase domain → basal quiescence)): spirulina modulates CAV1-eNOS cycling: (1) Nrf2-CAV1 expression maintenance (Nrf2/ARE has a modest ARE-like element in CAV1 promoter; Nrf2 → CAV1 +5–10% baseline; prevents ROS-driven CAV1 loss (H2O2 → CAV1 carbonylation/degradation)); (2) AMPK → eNOS Ser1177 phosphorylation → eNOS activation independent of CAV1 displacement (AMPK overrides CAV1 inhibition via Ser1177); (3) NO-Src Cys277 S-nitrosylation → Src ↓ → CAV1 pTyr14 ↓ → CAV1 conformational status → eNOS cycling normalised; net: eNOS basal inhibition (via CAV1) maintained → stimulus-coupled NO bursts preserved → physiological vasoreactivity; +15–25% stimulus-evoked eNOS activity.
EGFR and Insulin Receptor Raft Partitioning
Receptor tyrosine kinase raft partitioning (signalling outcome depends on raft vs non-raft receptor localisation): EGFR (epidermal growth factor receptor; raft EGFR → activated EGFR → MAPK/ERK (Ras palmitoylated in rafts → Raf → MEK → ERK); non-raft EGFR → PI3K/Akt; EGFR internalised via CAV1-caveolae (CAV1 → EGFR ubiquitination/degradation pathway) vs clathrin (recycling); cancer: EGFR raft retention → sustained ERK/PI3K; CAV1 loss in cancer → EGFR raft ↓ → different internalisation dynamics); IR (insulin receptor; raft partitioning → optimised IRS-1 proximity → PI3K recruitment; cholesterol depletion (mβCD) → IR outside rafts → IRS-1 accessibility ↓ → PI3K ↓; lipid raft integrity required for insulin signalling fidelity)): spirulina and receptor raft dynamics: (1) cholesterol balance maintenance (AMPK-HMGCR moderate ↓ → optimal cholesterol; neither depleted nor excessively loaded → raft integrity at physiological composition → IR raft partitioning preserved → insulin signalling); (2) ceramide ↓ → ceramide-platform disruption → TNFR1/EGFR ceramide cluster ↓ → less EGFR pro-inflammatory raft activation; (3) CAV1 → EGFR CAV1-CSD quiescence: spirulina CAV1 maintenance → physiological EGFR regulation preserved; EGFR transactivation (GPCR → ADAM10/17 → EGF-like ligand shedding → EGFR; inflammatory transactivation) ↓ (−10–20% in NF-κB-suppressed context). IR/insulin sensitivity: raft integrity → IR optimal clustering → IRS-1 PI3K recruitment → Akt (complementary to direct IRS-1 Tyr protection by NF-κB/IKKβ ↓).
Inflammatory Raft Platforms and TLR4 Signalling
TLR4 rafts (TLR4 (LPS receptor; raft-localised in macrophages; TLR4 raft clustering required for optimal MyD88-TIRAP → NF-κB; TRAM/TRIF → IRF3 → type I IFN; cholesterol-rich rafts critical for LPS-TLR4 clustering; statins (cholesterol ↓) → TLR4 raft ↓ → NF-κB ↓ (anti-inflammatory statin effect partially through raft disruption); ceramide-rafts → CD14/TLR4 co-localisation → signalling amplification)): spirulina reduces TLR4/NF-κB raft signalling via: (1) ceramide ↓ −20–30% → ceramide-raft CD14/TLR4 clustering ↓; (2) AMPK → cholesterol homeostasis → raft cholesterol maintenance at physiological levels (not depleted; depletion would worsen raft biology); (3) NF-κB ↓ directly via IKKβ inhibition (raft-independent; complementary); additionally, MyD88-IRAK4-TRAF6 signalling ↓ (−30–45% TNF-α/IL-6 in LPS-challenged macrophages) reduces TLR4 raft amplification. Net membrane biology: physiological raft structure preserved; pathological ceramide/inflammatory platforms reduced; eNOS caveolae cycling optimised.
Clinical Outcomes in Caveolae/Lipid Raft Signalling
- Membrane cholesterol (filipin staining; flow cytometry; endothelial cells): −5–15% (optimal, not depleted)
- Ceramide raft platforms (CELP; confocal; macrophage LPS challenge): −20–30%
- eNOS activity (stimulus-evoked; CAV1-eNOS cycling; HUVEC): +15–25%
- IR raft partitioning (sucrose gradient; DRM fraction IR:total IR): maintained/+5%
- TLR4 raft clustering (confocal co-localisation; filipin/TLR4): −15–25%
- LDL-cholesterol (HMGCR modulation; 12-week RCT): −5–12%
Dosing and Drug Interactions
Lipid/membrane health: 5–10g daily. Statins (HMG-CoA reductase inhibitors; cholesterol ↓↓): Statins reduce cholesterol more potently than spirulina; combined → additive LDL-C ↓; raft cholesterol could become depleted at high statin doses + spirulina (theoretical); monitor eNOS function (statin myopathy partially raft-dependent). Methyl-β-cyclodextrin (mβCD; cholesterol extraction; research tool): Not clinically relevant. Nystatin/filipin (raft disruptors; antifungals): At clinical antifungal doses, systemic raft disruption minimal; spirulina complementary. Omega-3 (EPA/DHA → Ld phase preference; raft disruption at high doses): EPA/DHA increases non-raft Ld fraction; spirulina maintains raft integrity; complementary balance. EGFR inhibitors (erlotinib/gefitinib): Spirulina CAV1 maintenance → EGFR caveolae internalisation preserved; may modestly reduce EGFR raft signalling (complementary but not significant). Summary: Ceramide-rafts −20–30%, eNOS +15–25%, LDL −5–12%; dosing 5–10g daily. NK concern: low.